Anti-aging cosmetic composition

Abstract

The present invention relates to a composition for strengthening the dermis layer of the skin by strengthening the basement membrane of the skin, thereby improving skin elasticity or skin wrinkles. The composition according to the present invention contains a compound represented by Chemical formula 1, a compound represented by Chemical formula 2 and / or a compound represented by Chemical formula 3, and thus has a better effect of improving skin elasticity or wrinkles than a composition containing only the compound represented by Chemical formula 1, only the compound represented by Chemical formula 2 or only the compound represented by Chemical formula 3.

Description

Technical Field

[0001] The present invention relates to a composition that strengthens the dermis of the skin by strengthening the skin basement membrane and improves skin elasticity or skin wrinkles.

Background Art

[0002] Collagen is a major matrix protein produced by skin fibroblasts and exists in the extracellular matrix. Collagen is known to play important functions related to the mechanical firmness of the skin, the resistance and tissue binding force of connective tissues, the support of cell adhesion, and the induction of cell division and differentiation (during the growth of an organism or the healing of a wound). Such collagen is a fibrous protein found abundantly in mammals and constitutes bones, cartilage, basement membranes, etc. in the body.

[0003] Among them, the skin basement membrane plays an important role in the support and adhesion of epidermal cells, the movement of nutrients, and the regulation of epidermal differentiation. When the skin basement membrane is damaged by aging, flattening, multiplexing, heat insulation, etc. of the basement membrane occur, wrinkles are generated, and there is a high possibility that external risk factors will penetrate to the dermis, and the skin may be easily damaged. Therefore, in order to restore or maintain the damaged skin basement membrane in a healthy state, first, its components need to be properly maintained.

[0004] On the other hand, fibroblast growth factor (FGF) is one of the growth factors that regulate the proliferation, migration, differentiation, and survival of various cells, and is composed of a group of 23 proteins. FGF is produced in keratinocytes, fibroblasts, vascular endothelial cells, smooth muscle cells, chondrocytes, and mast cells, and exerts the above-mentioned functions by activating four types of fibroblast growth factor receptors (FGF receptors) that are expressed in various cells. In particular, FGF2, FGF7, and FGF10 are known to play important roles in skin regeneration (Non-Patent Literature 1). FGF7 and FGF10 promote the proliferation of keratinocytes and are involved in the re-epithelialization process, and are also involved in the process of neutralizing reactive oxygen species and maintaining keratinocytes.

[0005] Conventional technologies aim to improve skin elasticity or wrinkles through collagen, and such collagen synthesis-promoting methods are primarily characterized by strengthening the epidermal layer. However, a problem has been found that strengthening only the epidermal layer does not always lead to improved skin elasticity or wrinkle reduction when applied to actual skin. Therefore, there is an urgent need for the development of anti-aging skin compositions that strengthen the dermis layer by strengthening the actual skin basement membrane, thereby improving skin elasticity or wrinkles. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] 1: Barrientos S, Stojadinovic O, Golinko M, Brem H, Vinay Tomic-Canic M.2008. Growth factors and cytokines in wound healing. Wound Rep Reg.16:585 [Overview of the Initiative] [Problems that the invention aims to solve]

[0007] Therefore, the present inventors have strived to obtain a composition that strengthens the skin basement membrane and exhibits anti-aging effects such as skin elasticity improvement or wrinkle improvement. As a result, they have confirmed that cordycepin, represented by Chemical Formula 1, andrographolide, represented by Chemical Formula 2, and quercetin, represented by Chemical Formula 3, exhibit skin elasticity improvement or wrinkle improvement effects. In particular, they have confirmed that when the compound represented by Chemical Formula 1, the compound represented by Chemical Formula 2, and / or the compound represented by Chemical Formula 3 are used in combination, there is an excellent effect in strengthening the dermis layer of the skin, improving skin elasticity, and improving wrinkles, thus completing the present invention.

[0008] Therefore, the object of the present invention is to provide a cosmetic composition for improving skin elasticity or wrinkles, comprising as an active ingredient a compound represented by Chemical Formula 1 or a physiologically acceptable salt thereof, a compound represented by Chemical Formula 2 or a physiologically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a physiologically acceptable salt thereof.

[0009] A further object of the present invention is to provide a pharmaceutical composition for improving skin elasticity or wrinkles, comprising as an active ingredient a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof. [Means for solving the problem]

[0010] To achieve the above-mentioned objectives of the present invention, the present invention provides a cosmetic composition for improving skin elasticity or wrinkles, comprising as an active ingredient a compound represented by Chemical Formula 1 or a physiologically acceptable salt thereof, a compound represented by Chemical Formula 2 or a physiologically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a physiologically acceptable salt thereof.

[0011] Furthermore, the present invention provides a pharmaceutical composition for improving skin elasticity or wrinkles, comprising as an active ingredient a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof.

[0012] The present invention provides a method for improving skin elasticity or wrinkles, comprising the step of treating the skin with a cosmetic composition containing as an active ingredient a compound represented by Chemical Formula 1 or a physiologically acceptable salt thereof, a compound represented by Chemical Formula 2 or a physiologically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a physiologically acceptable salt thereof.

[0013] The present invention provides a method for improving skin elasticity or wrinkles, comprising the step of administering a pharmaceutical composition containing as an active ingredient a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof.

[0014] The present invention provides uses for compositions containing as active ingredients a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof, for the production of products for improving skin elasticity or wrinkles.

[0015] [ka]

[0016] The compound represented by the above formula 1 is a molecular formula C 10 H 13 It has N5O3, a molecular weight of 251.12 g / mol, and is named cordycepin, 3'-deoxyadenosine, 3'-deoxy-adenosine9-cordyceposidoadenine, 9-(3-Deoxy-bD-erythro-pentofuranosyl)-9Hpurin-6-amine, 9-(3-Deoxy-bD-ribofuranosyl)adenine, etc.

[0017] The present invention is not particularly limited to the method of obtaining cordycepin, which may be chemically synthesized by methods known in the art, or a commercially available substance may be used.

[0018] In the composition according to the present invention, the content of the colchicine may be 0.00001 to 10% by weight, for example, 0.00001 to 8% by weight, 0.00001 to 5% by weight, 0.00001 to 3% by weight, 0.00001 to 2% by weight, 0.00001 to 1% by weight, or 0.00002 to 1% by weight, based on the total weight of the composition.

[0019]

Chemical formula

[0020] The compound represented by Chemical formula 2 has a molecular formula of C 20 H 30 O5, a molecular weight of 350.45 g / mol, and is named andrographolide, 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone, etc.

[0021] The present invention is not particularly limited to the method for obtaining the andrographolide, and it may be chemically synthesized by a method known in the art or a commercially available substance may be used.

[0022] In the composition according to the present invention, the content of the andrographolide may be 0.0 by weight.00001 to 10% by weight, for example, 0.00001 to 8% by weight, 0.00001 to 5% by weight, 0.00001 to 3% by weight, 0.00001 to 2% by weight, 0.00001 to 1% by weight, or 0.00002 to 1% by weight, based on the total weight of the composition.

[0023]

Chemical formula

[0024] The compound represented by formula 3 above has molecular formula C 15 H 10 It has a molecular weight of 302.236 g / mol and is named quercetin, 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one,3,3',4',5,7-Pentahydroxyflavone,5,7,3',4'-flavon-3-ol, etc.

[0025] The present invention is not particularly limited to the method of obtaining quercetin, which may be chemically synthesized by methods known in the art, or a commercially available substance may be used.

[0026] In the composition according to the present invention, the quercetin content may be 0.00001 to 10% by weight of the total weight of the composition, for example, 0.00001 to 8% by weight, 0.00001 to 5% by weight, 0.00001 to 3% by weight, 0.00001 to 2% by weight, 0.00001 to 1% by weight, or 0.00002 to 1% by weight.

[0027] Furthermore, the composition according to the present invention may contain the compound represented by formula 1 or a pharmaceutically acceptable salt thereof and the compound represented by formula 2 or a pharmaceutically acceptable salt thereof in a weight ratio of 100:1 to 1:100 or 50:1 to 1:50. The composition according to the present invention may contain the compound represented by formula 1 or a pharmaceutically acceptable salt thereof and the compound represented by formula 3 or a pharmaceutically acceptable salt thereof in a weight ratio of 100:1 to 1:100 or 50:1 to 1:50. The composition according to the present invention may contain the total amount of the compound represented by formula 1 or a pharmaceutically acceptable salt thereof, the compound represented by formula 2 or a pharmaceutically acceptable salt thereof, and the compound represented by formula 3 or a pharmaceutically acceptable salt thereof in a weight ratio of 100:1 to 1:100 or 50:1 to 1:50.

[0028] In the present invention, "skin elasticity improvement effect" means preventing, suppressing, or inhibiting a decrease in skin elasticity, or increasing skin elasticity that has already decreased.

[0029] In the present invention, "wrinkle-improving effect" means preventing, suppressing, or inhibiting the formation of wrinkles on the skin, or alleviating wrinkles that have already formed.

[0030] According to one embodiment of the present invention, it was confirmed that when human fibroblasts were treated with cordycepin, a compound represented by Chemical Formula 1, the mRNA expression of FGF 10 was promoted. It was also confirmed that when human fibroblasts were treated with androphagolide, a compound represented by Chemical Formula 2, the mRNA expression of FGF 10 was promoted. It was also confirmed that when human fibroblasts were treated with quercetin, a compound represented by Chemical Formula 3, the mRNA expression of FGF 10 was promoted. Furthermore, it was confirmed that when human fibroblasts were treated with cordycepin along with androphagolide or quercetin, the mRNA expression level of FGF 10 increased even further than that of cordycepin alone, androphagolide alone, and quercetin alone.

[0031] FGF-10 is expressed in fibroblasts that make up the dermis and is known to play a role in strengthening and maintaining the normal function of the skin basement membrane. Furthermore, FGF-10 plays a role in maintaining skin integrity through signal transduction between the epidermis and dermis, and interacts with heparin sulfate, a major proteoglycan that makes up the basement membrane, to participate in the growth, division, adhesion, and migration of epidermal cells. Generally, FGF-10 expression is known to maintain the normal function of the basement membrane itself and to promote epidermal growth by transmitting signals through the basement membrane.

[0032] Therefore, the composition of the present invention can cause FGF 10 to be expressed and promote the proliferation of fibroblasts in the skin basement membrane, thereby strengthening the skin basement membrane and exhibiting effects on improving skin elasticity or wrinkles.

[0033] Therefore, the composition of the present invention may simultaneously contain the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and the compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, or the compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof, and the composition has an even better skin elasticity or wrinkle improvement effect than a composition containing the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, the compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, or the compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof alone.

[0034] The compositions according to the present invention may be manufactured in dosage forms selected from the group consisting of solutions, topical ointments, creams, foams, nourishing lotions, softening lotions, packs, softening waters, emulsions, makeup bases, essences, soaps, cleansing agents, bath additives, sunscreen creams, sun oils, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, patches, and sprays. Preferably, they may be lotions, essences, creams, packs, gels, powders, foundations, or cleansing agents, but are not limited thereto.

[0035] In the present invention, the cosmetic composition may further contain one or more cosmetically acceptable carriers that are incorporated into general skin cosmetics, and may, but is not limited to, oils, water, surfactants, humectants, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc., as usual ingredients.

[0036] When the dosage form of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as the carrier component, and especially in the case of a spray, it may further contain propellants such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0037] When the dosage form of the present invention is a solution or emulsion, a solvent, solubilizer, or emulsifier is used as the carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, and especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol, or sorbitan fatty acid esters.

[0038] When the dosage form of the present invention is a suspension, the carrier component may be a liquid diluent such as water, ethanol, or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester; or microcrystalline cellulose, aluminum methhydroxyl, bentonite, aga, or tracant.

[0039] When the dosage form of the present invention is soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc., may be used as carrier components.

[0040] The present invention provides a method for improving skin elasticity or wrinkles, further comprising the step of treating the skin of an individual with a cosmetic composition containing as an active ingredient a compound represented by the following formula 1 or a physiologically acceptable salt thereof, a compound represented by the following formula 2 or a physiologically acceptable salt thereof, and / or a compound represented by the following formula 3 or a physiologically acceptable salt thereof. The individual includes, without limitation, mammals such as humans, livestock, and mice.

[0041] The present invention provides applications for cosmetic compositions containing, as active ingredients, a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof, for the production of products for improving skin elasticity or wrinkles.

[0042] On the other hand, the pharmaceutical composition of the present invention may contain the active ingredient alone, or may further contain pharmaceutically acceptable carriers, excipients, diluents, or auxiliary components depending on the dosage form, method of use, and purpose of use.

[0043] More specifically, in addition to the active ingredients mentioned above, the product may further contain nutrients, vitamins, electrolytes, flavoring agents, coloring agents, enhancers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonating agents used in carbonated beverages.

[0044] The term "pharmaceutically acceptable" means that it is physiologically acceptable and, when administered to animals, preferably humans, does not usually cause allergic reactions or similar reactions such as gastrointestinal disorders or dizziness. The pharmaceutically effective amount may be appropriately varied depending on the disease and its severity, the patient's age, weight, health condition, sex, route of administration, or duration of treatment.

[0045] Examples of the pharmaceutically acceptable carriers, excipients, or diluents include, but are not limited to, at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, dextrin, calcium carbonate, propylene glycol, liquid paraffin and physiological saline. All ordinary carriers, excipients, or diluents can be used.

[0046] The aforementioned components may be added independently of or in combination with the active ingredients of the present invention.

[0047] The dosage form of the pharmaceutical composition may vary depending on the method of use and may be formulated using methods known in the art to which the present invention belongs, so as to provide rapid, sustained, or delayed release of the active ingredient after administration to a mammal. Examples of the dosage form may be selected from the group consisting of ointments, creams, tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, aqueous solutions, non-aqueous solvents, suspensions, emulsions, and patches.

[0048] For the aforementioned dosage form, the following may be further included: excipients, such as ordinary fillers, bulking agents, binders, disintegrants, surfactants, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, sweeteners, fragrances, or preservatives.

[0049] Generally, oral solid dosage forms include tablets, soft or hard capsules, pills, powders, and granules. Such preparations may be prepared by mixing one or more excipients, such as starch, calcium carbonate, sucrose, or lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

[0050] Furthermore, liquid formulations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to water or liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, flavorings, and preservatives may be included.

[0051] Examples of formulations suitable for skin administration include dusting powders, emulsions, suspensions, oils, sprays, ointments, glycyrrhizic ointments, creams, pastes, gels, foams, or solutions, as well as carriers and / or excipients suitable for transdermal therapeutic systems (TTS). The compositions of the present invention may also be in semi-solid formulations, particularly ointments (solution ointments, suspension ointments), creams, gels, or pastes. Those primarily used in the oil phase include fatty alcohols, such as lauryl alcohol, cetyl alcohol, stearyl alcohol; fatty acids, such as palmitic acid or stearic acid; liquid or solid paraffin or ozokerite; liquid or solid waxes, such as isopropyl myristate; natural or partially synthetic fats, such as coconut fatty acid triglycerides; hydrogenated oils, such as hydrogenated peanut or castor oil; or fatty acid partial esters of glycerol, such as glycerol monostearate or glycerol distearate. Suitable emulsifiers include surfactants, such as nonionic surfactants, such as fatty acid esters of polyalcohols or their ethylene oxide adducts, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid esters; sorbitan fatty acid esters, such as sorbitan oleate or sorbitan isostearate; isostearates, sterols; or polyoxyethylene fatty alcohol ethers or fatty acid esters, such as anionic surfactants, such as alkali metal salts of fatty alcohol sulfonates, such as sodium lauryl sulfate, sodium cetyl sulfate, or sodium stearyl sulfate, which are commonly used in the presence of fatty alcohols, such as cetyl alcohol or stearyl alcohol. Among these, formulations that particularly prevent cream drying can be made by adding polyalcohols, such as glycerol, sorbitol, propylene glycol, or polyethylene glycol to the aqueous phase, or by adding preservatives, fragrances, etc., to the aqueous phase.

[0052] The pharmaceutical composition of the present invention may be an anhydrous ointment, suitable for topical use, and may contain paraffin, particularly low-viscosity paraffin, which is liquid at body temperature, or may contain natural or partially synthetic fats, such as coconut fatty acid triglycerides, hydrogenated oils, such as hydrogenated peanut or castor oil, fatty acid partial esters of glycerol, such as glycerol monostearate and distearate, silicones, such as polymethylsiloxane, such as hexamethyldisiloxane or octamethyltrisiloxane, and may also contain fatty alcohols that increase water absorption capacity, such as those related to aqueous creams, and sterols, wool wax, other emulsifiers and / or other additives.

[0053] In the present invention, when the pharmaceutical composition is put into dosage form as a pharmaceutical product, reference may be made to the contents disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, which are included as part of this specification.

[0054] The present invention provides a method for improving skin elasticity or wrinkles, further comprising the step of administering to an individual a pharmaceutical composition containing as an active ingredient a compound represented by the following formula 1 or a pharmaceutically acceptable salt thereof, a compound represented by the following formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by the following formula 3 or a pharmaceutically acceptable salt thereof. The individual includes, without limitation, mammals such as humans, livestock, and mice.

[0055] The present invention provides applications for a pharmaceutical composition containing as an active ingredient a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, a compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, and / or a compound represented by Chemical Formula 3 or a pharmaceutically acceptable salt thereof, for the production of a product for improving skin elasticity or wrinkles.

[0056] In the present invention, the term "pharmaceutical composition" may be used as a concept that includes the meaning of "quasi-drug" or "pharmaceutical product."

[0057] When the composition of the present invention is used as a dosage form for topical skin preparations, it may further contain adjuvants commonly used in dermatology, such as fatty substances, organic solvents, solvents, concentrates and gelling agents, softeners, antioxidants, suspension agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic surfactants, lipid vesicles, or any other components commonly used in topical skin preparation compositions. Furthermore, these components may be introduced in amounts commonly used in dermatology.

[0058] Furthermore, when the composition of the present invention is provided as an external preparation composition, it may have the dosage form of an ointment, patch, gel, cream, or spray, but is not limited thereto.

[0059] The topical formulation composition of the present invention may be used as a parenteral formulation, for example, by a conventional method for producing topical skin formulations, which involves homogeneously mixing a suitable pharmaceutically acceptable base such as petrolatum and stearyl alcohol, a suitable pharmaceutically acceptable surfactant such as polysorbate and sorbitan sesquioleate, a suitable pharmaceutically acceptable humectant such as glycerin, a suitable pharmaceutically acceptable solvent, and a fragrance, colorant, stabilizer, viscous agent, etc.

[0060] On the other hand, when the composition of the present invention is provided as a quasi-drug composition, in addition to containing at least one compound selected from the group consisting of hydroxycinnamic acid, isoamyl acetate, and betaine or a pharmaceutically acceptable salt thereof as an active ingredient, it may further contain a pharmaceutically acceptable carrier, excipient, or diluent as needed. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effects of the present invention, and may include, for example, fillers, bulking agents, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, and the like.

[0061] The quasi-drug composition mentioned above includes disinfectants, cleansing agents, shower foams, ointments, wet wipes, and coating agents. Preferably, it may be manufactured as a semi-solid preparation such as an external ointment or lotion, but is not limited thereto. The formulation method, dosage, method of use, and components of the quasi-drug may be appropriately selected from common techniques known in the art.

[0062] In this invention, the term "quasi-drug" refers to an article that exhibits therapeutic, alleviating, treating, or preventive effects on a disease, but whose effects on the human body are less severe than those of a pharmaceutical product. This includes articles classified according to the Ministry of Health and Welfare's classification standards, excluding articles used as pharmaceuticals under the Pharmaceutical Affairs Law. Specifically, this may include, but is not limited to, topical skin preparations or personal hygiene products.

[0063] Each of the components contained in the cosmetic composition according to the present invention may preferably be included in the cosmetic composition according to the present invention within a range that does not exceed the maximum amount specified in the regulations related to "cosmetic use and authorization" prescribed by each national government. For example, it may comply with the range specified in the "Cosmetic Safety Technical Specifications" prescribed by the Chinese government.

[0064] In summary, unless otherwise specified, the numerical values ​​described herein should be interpreted as including an equal range. [Effects of the Invention]

[0065] The present invention provides a composition comprising a compound represented by Chemical Formula 1, a compound represented by Chemical Formula 2, and / or a compound represented by Chemical Formula 3. The composition exhibits even better skin elasticity or wrinkle improvement effects than compositions comprising the compound represented by Chemical Formula 1 alone, the compound represented by Chemical Formula 2 alone, or the compound represented by Chemical Formula 3 alone. [Brief explanation of the drawing]

[0066] [Figure 1]Figure 1 compares the results of treating the basement membrane with and without cordycepin and androphagolide after UV irradiation. [Modes for carrying out the invention]

[0067] The present invention will be described in detail below with reference to the following examples. However, the following examples are illustrative of the present invention, and the content of the present invention is not limited to the following examples. [Examples]

[0068] Experimental Example 1: Analysis of FGF10 mRNA expression Human dermal fibroblasts, neonatal, were purchased from Lonza and cultured in a carbon dioxide incubator at 37°C under 5% carbon dioxide conditions. The culture medium used was DMEM (Dulbecco Modified Eagle Medium-Thermo Fisher Scientific) mixed with 10% FBS (Fetal Bovine Serum) and 1% Antibiotics (Penicillin streptomycin). Next, 20,000 cells were planted in a 6-well plate and, after 24 hours, the DMEM culture medium was treated with samples containing the components shown in Tables 1 and 2, and cultured again for a further 48 hours. A control group used DMEM medium without any other added components. Next, intracellular RNA was purified to synthesize cDNA, and then FGF10 mRNA expression levels were analyzed using qPCR. Table 1 shows the expression levels compared to the control group when treated with cordycepin and androglavolide individually and together. Table 2 shows the expression levels of cordycepin and quercetin when treated individually and together, compared to the control group. Adenosine is a substance well known to have an effect on improving skin wrinkles in conventional techniques, but it was confirmed that it does not have the effect of increasing FGF10 expression.

[0069] [Table 1]

[0070] [Table 2]

[0071] Experimental Example 2: Analysis of basement membrane changes using pig skin. Live pig skin (not frozen after slaughter and used immediately for experiments) was purchased from Apuas and cultured in a carbon dioxide incubator at 37°C under 5% carbon dioxide conditions using a culture medium prepared by mixing 10% FBS (Fetal Bovine Serum), 1% Antibiotics (Penicillin streptomycin), and 0.02% Tetracyclin in DMEM (Dulbecco Modified Eagle Medium-Thermo Fisher Scientific). After stabilizing the pig skin in a 6-well hanging insert (MILLIPORE) for 24 hours, UVB was applied at 1 J / cm² using a UV irradiation device. 2 The basement membrane was irradiated at an intensity to induce destruction. UV irradiation was performed a total of three times, with 5 minutes of irradiation followed by a 2-hour rest period. Immediately after UVB irradiation, a sample containing 0.1% cordycepin and 0.1% andrgradolide was applied to the surface of pig skin and treated for 48 hours. Next, samples were taken, fixed with 10% formalin, and then H&E staining was requested from TEGO Science. During the experiment, the DMEM was changed once in the morning and once in the afternoon. The experimental results are shown in Figure 1. When the basement membrane is irradiated with UV, it becomes flattened; however, when treated with cordycepin and andrgradolide, the flattened basement membrane recovers.

[0072] Experimental Example 3. Evaluation of the effect on improving elasticity or wrinkles in human skin. To evaluate the skin-improving effect due to the basement membrane strengthening effect in human skin, the following manufacturing examples were produced (unit: weight %).

[0073] [Table 3]

[0074] Thirty-two women aged 27-43 years used the cosmetic product described in Table 3 on their faces once in the morning and once in the evening, for a total of two times a day, for four weeks. Skin wrinkles and skin elasticity were measured. Measurements were taken once immediately before the first day of use (A) and again after the four weeks of use were completed (B). The measurement method was as follows: For skin wrinkle measurement, residual wrinkles (latent wrinkles) caused by facial expressions were measured once at the test site (around the eyes) using an Antera 3DCS (Miravex, Ireland) system, and the depth (depth, mm) in Wrinkle-small analysis mode was used as evaluation data. The subjects artificially created wrinkles around their eyes by making a frowning face, maintained the wrinkles for one minute, and then measured the residual wrinkles immediately after relaxing their facial expression. The measuring device uses a light-emitting diode (LED light source) to measure the surface image of the skin. Data was extracted from the built-in program's 3D shape image, and the skin condition was quantified and utilized in the image. A decrease in wrinkle depth (mm) value after 4 weeks compared to before product use indicates that residual wrinkles (latent wrinkles) caused by facial expressions have improved. Skin elasticity was measured using a dermal torque meter (Dia-Stron, United Kingdom), and the test area (cheek) was measured three times, with the average value used as evaluation data. The measurement principle uses a torsional method between a 3mm guard ring and a central disk. The Ur / Ue value was used as an evaluation index for the inner elasticity of the skin, and an increase in the measured value indicates that the inner elasticity of the skin has improved.

[0075] The measurement results were used to calculate the improvement rate, which is shown in Table 4 below.

[0076]

number

[0077] Table 4

Claims

1. A composition for strengthening the skin basement membrane, comprising as an active ingredient a compound represented by the following chemical formula 1 or a physiologically acceptable salt thereof, and a compound represented by the following chemical formula 2 or a physiologically acceptable salt thereof and / or a compound represented by the following chemical formula 3 or a physiologically acceptable salt thereof. 【Chemistry 1】 【Chemistry 2】 【Transformation 3】

2. The composition for strengthening the skin basement membrane according to claim 1, wherein the content of the compound represented by formula 1 or a physiologically acceptable salt thereof is 0.00001% to 10% by weight of the total composition, and the content of the compound represented by formula 2 or a physiologically acceptable salt thereof and / or the compound represented by formula 3 or a physiologically acceptable salt thereof is 0.00001% to 10% by weight of the total composition.

3. The skin basement membrane strengthening composition according to claim 1, comprising a compound represented by formula 1 or a physiologically acceptable salt thereof, and a compound represented by formula 2 or a physiologically acceptable salt thereof and / or a compound represented by formula 3 or a physiologically acceptable salt thereof in a weight ratio of 100:1 to 1:100.

Images